Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Retrospective Analysis of the Correlation of MSI-H/dMMR Status and Response to Therapy for Endometrial Cancer: RAME Study, a Multicenter Experience

Version 1 : Received: 12 June 2023 / Approved: 13 June 2023 / Online: 13 June 2023 (12:27:39 CEST)

A peer-reviewed article of this Preprint also exists.

Tuninetti, V.; Pace, L.; Ghisoni, E.; Quarà, V.; Arezzo, F.; Palicelli, A.; Mandato, V.D.; Geuna, E.; Cormio, G.; Biglia, N.; Borsotti, L.; Gallo, S.; Ferrero, A.; Jacomuzzi, E.; Fuso, L.; Pezua Sanjinez, J.O.S.; Puppo, A.; Caglio, A.; Rognone, C.; Turinetto, M.; Scotto, G.; Di Maio, M.; Valabrega, G. Retrospective Analysis of the Correlation of MSI-h/dMMR Status and Response to Therapy for Endometrial Cancer: RAME Study, a Multicenter Experience. Cancers 2023, 15, 3639. Tuninetti, V.; Pace, L.; Ghisoni, E.; Quarà, V.; Arezzo, F.; Palicelli, A.; Mandato, V.D.; Geuna, E.; Cormio, G.; Biglia, N.; Borsotti, L.; Gallo, S.; Ferrero, A.; Jacomuzzi, E.; Fuso, L.; Pezua Sanjinez, J.O.S.; Puppo, A.; Caglio, A.; Rognone, C.; Turinetto, M.; Scotto, G.; Di Maio, M.; Valabrega, G. Retrospective Analysis of the Correlation of MSI-h/dMMR Status and Response to Therapy for Endometrial Cancer: RAME Study, a Multicenter Experience. Cancers 2023, 15, 3639.

Abstract

Background: There is poor evidence about sensitivity to chemotherapy according to microsatellite instability (MSI)/mismatch repair (MMR) status in endometrial cancer (EC). Methodology: The RAME study is a retrospective analysis aiming to assess response to chemotherapy in MSI-high (h) /deficient (d) MMR and MSI- low (l)/proficient (p)MMR EC patients. Primary endpoints were recurrence-free survival (RFS) for patients with localized disease and progression-free survival (PFS) and overall survival (OS) in patients with advanced/recurrent disease. Results: 312 patients treated between 2010-2022 in 4 high volume Multicenter Italian Trial in Ovarian cancer and gynecological malignancies (MITO) centers were selected. 239 patients had endometrioid EC (76.6%), 151 had FIGO stage I at diagnosis (48.9%) and 71 were MSI-h/dMMR (22.8%). Median age was 65 (range 31–91) years. Among patients with localized disease, median RFS was 100.0 months (95%CI 59.4–140.7) for MSI-l/pMMR and 120.9 months (60.0-181.8) for MSI-h/dMMR (p=0.39). Seventy-seven patients received first-line chemotherapy for advanced/recurrent disease. Patients with MSI-h/dMMR ECs had a significantly worse OS (p=0.039). In patients receiving platinum-based chemotherapy, no statistically significant difference in PFS (p=0.21) and OS (p=0.057) were detected, although PFS and OS were numerically longer in the MSI-l/pMMR population. Conclusion: Patients with metastatic MSI-h/dMMR EC receiving first-line chemotherapy had a significantly worse OS.

Keywords

Endometrial cancer; microsatellite instability; mismatch repair deficiency; platinum-based chemotherapy

Subject

Medicine and Pharmacology, Oncology and Oncogenics

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.